EMEA and FDA extend drug-label based on results of the EORTC 24971 trial
In its September meeting 2006, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) gave a positive opinion to include the use of docetaxel in combination with the current standard treatment - cisplatin and 5 fluorouracil for the induction treatment of patients with inoperable locally advanced squamous cell carcinoma of the head and neck. On October...